- The Barn Holly Berry House Rough Park,
Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ - 666-888-0000
- info@elarapharma.com
- info@elarapharma.com
- The Barn Holly Berry House Rough Park,
Hamstall Ridware, Rugeley, Staffordshire, WS15 3SQ - Contact Us
Nov2022
CY6463 administration is linked to improvements in Alzheimer’s disease-relevant biomarkers, as revealed by eXplainable AI-driven analysis of multiple Phase 1 clinical trials
• Phase 1 studies show improvement in cognitive factors, consistent with therapeutic potential of CY6463 to improve key features in neurological diseases
• CY6463 favorable tolerability and safety profile was confirmed
Apr2020
Towards a first precision medicine treatment of Alzheimer’s disease using Tersan’s Explainable AI.
Paris and Boston, April 17th 2020. Tersan® Pharma, a leading digital health company announced today the publication of the first reported genome-wide search for biomarkers associated with drug response in Alzheimer’s disease in the Alzheimer’s & Dementia: Translational Research & Clinical Interventions journal. Using Tersan’s proprietary KEM® (Knowledge Extraction and Management) advanced Artificial Intelligence technology, […]
Jul2019
Alzheimer’s Disease/Dementia Early Detection and Precision Medicine Using KEM® Artificial Intelligence (AI): latest research results presented by ARIANA at the AAIC 2019.
Gut Microbiota biomarkers associated with improved drug response, as well as genomic biomarkers for early detection of patients at risk were identified using Tersan’s KEM® Explainable AI (XAI) in 3 separate oral presentations. response, as well as genomic biomarkers for early detection of patients at risk were identified using Tersan’s KEM® Explainable AI (XAI) in […]
Oct2018
Tersan’s AI provides evidence for 3 years clinical efficacy of ANAVEX®2-73 Alzheimer’s targeted therapy @CTAD2018
Precision medicine approach using Tersan’s AI KEM® shows that a small data rich open label clinical study of 32 well-characterized patients may be sufficient to identify strong biomarker hypothesis identifying patients with the highest chance of benefiting from the drug. BARCELONA, October 26th, 2018. Dr Mohammad Afshar presented 3 years longitudinal data of clinical […]
Sep2018
Artificial Intelligence enables first biomarker driven precision medicine therapy against Alzheimer
Elara Pharmaceuticals Ltd helps ANAVEX® demonstrate efficacy of its Alzheimer’s therapy in phase 2a clinical trial. Tersan’s KEM® Artificial Intelligence technology has resulted in the identification of the first actionable genetic variant biomarkers, selecting a specified Alzheimer’s disease population, who demonstrated a confirmed response with ANAVEX®2-73. Professor Harald Hampel, M.D., Ph.D., presenting results at the AAIC […]
Aug2018
Applying the cancer playbook to find treatment for Alzheimer’s disease
Applying the cancer playbook to find treatment for Alzheimer’s disease: see how Tersan’s KEM Artificial Intelligence platform is helping Anavex Life Sciences develop the first targeted therapy against Alzheimer’s disease. “NEW YORK – July 25, 2018 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics […]
Nov2017
CTAD 2017 (Boston, USA | 1-4 Nov)
Dr Mohammad Afshar (Tersan CEO) is presenting on the analysis of Phase 2a trial results using Tersan’s KEM® artificial intelligence platform at CTAD 2017 (10th Clinical Trials on Alzheimer’s Disease) in Boston, USA on 4 November. LB18 – Clinical Pharmacokinetics and Pharmacodynamics Characterization of ANAVEX™2-73 for Designing a Phase 2/3 Study in Mild-to-Moderate Alzheimer’s Disease […]
Oct2017
Anavex incorporating Tersan’s KEM® AI platform in Alzheimer’s precision medicine approach
Anavex Life Sciences Reports PK and PD Data from Phase 2a Trial of ANAVEX®2-73 in Mild-to-Moderate Alzheimer’s Disease PatientsANAVEX2-73 demonstrates desirable PK/PD properties, describing the relationship between drug concentration and the effect observed.Anavex is incorporating advanced Artificial Intelligence platform for the analysis of Phase 2a results with the aim to increase the chances of success […]
Oct2016
Anavex and Elara Pharmaceuticals Ltd Collaborate to Accelerate Timelines and Improve Efficiency of Alzheimer’s and Parkinson’s Clinical Development Programs
NEW YORK, NY – October 5, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced a collaboration with Elara Pharmaceuticals Ltd […]